SCT | Jotup

Palliser Capital Supports Shareholder Proposals to Reduce Samsung C&T’s Value Gap

Retrieved on:

Monday, March 4, 2024

The Shareholder Proposals are consistent with recommendations Palliser presented in December 2023 to unlock value and catalyze growth at SCT.

Key Points:

The Shareholder Proposals are consistent with recommendations Palliser presented in December 2023 to unlock value and catalyze growth at SCT.
The Shareholder Proposals comprise an important near-term initiative to help reduce the gap between SCT’s share price and its intrinsic market value, which is currently $22bn, equivalent to a 54% discount (the “SCT Value Gap”) and has consistently been in excess of 60%.
Unfortunately, SCT continues to trade at what Palliser believes is an unacceptable and excessively wide discount to its intrinsic value, with no cogent or transparent business strategy or plan to deliver long-overdue corporate value and improved shareholder returns.
We are fully supportive of the Shareholder Proposals and believe they represent important near-term initiatives to start addressing the Company’s persistent discount.

ISS and Glass Lewis Recommend Samsung C&T Shareholders Vote FOR Both Value-Enhancing Shareholder Proposals

Retrieved on:

Friday, March 1, 2024

Today, CLIM and Whitebox announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) have recommended that SCT shareholders vote for the Investor Group’s two value-enhancing shareholder proposals (the “Shareholder Proposals”) at the Company’s March 15, 2024 Annual General Meeting of Shareholders (the “Annual Meeting”).

Key Points:

Today, CLIM and Whitebox announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) have recommended that SCT shareholders vote for the Investor Group’s two value-enhancing shareholder proposals (the “Shareholder Proposals”) at the Company’s March 15, 2024 Annual General Meeting of Shareholders (the “Annual Meeting”).
Agenda Item 3: the allocation of KRW 500 billion to a share repurchase program during FY 2024.
Shareholders who intend to submit their votes for the 2024 Annual Meeting can download the proxy form and statements from the website .
THE VOTING DEADLINES SET BY THE VOTING AGENTS ARE NOT THE OFFICIAL VOTING DEADLINES SET BY THE COMPANY.

Investor Group Submits Value-Enhancing Shareholder Proposals for Consideration at Samsung C&T Corporation’s 2024 Annual General Meeting

Retrieved on:

Friday, February 2, 2024

Today, the Investor Group issued a letter to shareholders detailing the two value-enhancing proposals (the “Shareholder Proposals”) it has submitted for consideration at the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”).

Key Points:

Today, the Investor Group issued a letter to shareholders detailing the two value-enhancing proposals (the “Shareholder Proposals”) it has submitted for consideration at the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”).
The Investor Group encourages all stakeholders to visit www.UnlockSCTValue.com to share their views, sign up for important updates and learn about the proposals to help deliver enhanced value to SCT shareholders.
SCT possesses an exceptionally valuable portfolio of assets that includes strategic stakes in key Samsung group affiliates (notably Samsung Electronics and Samsung Biologics) and diverse business operations spanning areas such as Engineering & Construction and Trading.
This is equivalent to approximately 50% of annual FCF from operations (excluding Samsung Biologics) per SCT’s own estimates for FY 2023-2025.

MADISON RIVER CAPITAL MAKES STRATEGIC INVESTMENT INTO SENIOR CARE THERAPY

Retrieved on:

Thursday, January 11, 2024

LTC, Patient, SCT, Partnership, Long-term care, Mental health, MRC, Psychology, Mental, Elderly care, Growth, Nursing

Proceeds of the investment, along with additional operational resources from MRC, will be utilized to facilitate the continued expansion of SCT's high-quality mental health offering to residents in long term care ("LTC") facilities.

Key Points:

Proceeds of the investment, along with additional operational resources from MRC, will be utilized to facilitate the continued expansion of SCT's high-quality mental health offering to residents in long term care ("LTC") facilities.
The Braff Group, a leading mergers and acquisitions advisory firm, originated the transaction and acted as the exclusive mergers and acquisitions advisor to SCT.
The investment by MRC brings together strategic resources and capital to assist SCT's management team in continuing the growth of SCT's footprint with the goal of accelerating expansion of mental health services to an underserved population.
"This partnership has the skillsets and resources to make a huge impact on the delivery of critically needed mental health care to the underserved senior population.

Madison River Capital Makes Strategic Investment Into Senior Care Therapy

Retrieved on:

Wednesday, January 10, 2024

Senior, LTC, Partnership, Psychology, MRC, Elderly care, Long-term care, Mental health, Mental, SCT, Growth, Nursing

NEW YORK and ROCHELLE PARK, N.J., Jan. 10, 2024 /PRNewswire/ -- Madison River Capital ("MRC"), a lower middle market private equity firm focused on partnering with and building leading businesses across a variety of industries, today announced that funds affiliated with MRC have made an investment into Senior Care Therapy ("SCT"). SCT is a leading provider of patient-centered psychology and mental health services to the geriatric population in sub-acute, long-term care, and assisted living communities. Proceeds of the investment, along with additional operational resources from MRC, will be utilized to facilitate the continued expansion of SCT's high-quality mental health offering to residents in long term care ("LTC") facilities.

Key Points:

NEW YORK and ROCHELLE PARK, N.J., Jan. 10, 2024 /PRNewswire/ -- Madison River Capital ("MRC"), a lower middle market private equity firm focused on partnering with and building leading businesses across a variety of industries, today announced that funds affiliated with MRC have made an investment into Senior Care Therapy ("SCT").
SCT is a leading provider of patient-centered psychology and mental health services to the geriatric population in sub-acute, long-term care, and assisted living communities.
The investment by MRC brings together strategic resources and capital to assist SCT's management team in continuing the growth of SCT's footprint with the goal of accelerating expansion of mental health services to an underserved population.
"MRC's investment is a vote of confidence in the high-quality, patient-centric care that this company was built upon, and will allow us to accelerate access to much needed psychological and mental health services to the geriatric population," said Alisa Rosenfeld, Founder and CEO of Senior Care Therapy.

MAHLE at CES 2024: A System Champion for E-Mobility

Retrieved on:

Thursday, January 4, 2024

Magnet, Heat, Engineering, Peter Lynch, SAE International, Temperature, MCT, Application, Bionics, CES, SCT, Nature, Life, Electric motor

With its bionic battery-cooling plate, MAHLE has achieved a technological leap forward by using nature as a model.

Key Points:

With its bionic battery-cooling plate, MAHLE has achieved a technological leap forward by using nature as a model.
The company's all-new positioning system for wireless charging was recently chosen as the global standard technology by SAE International.
MAHLE's technology kit for electric motors featured at CES 2024 combines the advantages of the company's benchmark SCT and MCT electric motors.
SAE International, the US-based standards developing organization for engineering professionals, has chosen the MAHLE positioning system as the global standard solution for wireless charging.

Whitebox Advisors Sends Letter to Samsung C&T Corporation’s Board of Directors Regarding Immediate Opportunities to Enhance Shareholder Value

Retrieved on:

Wednesday, December 13, 2023

We are a long-term shareholder that has repeatedly sought to engage with SCT’s Board of Directors (the “Board”) and representatives of the management team in a constructive, private manner since 2017.

Key Points:

We are a long-term shareholder that has repeatedly sought to engage with SCT’s Board of Directors (the “Board”) and representatives of the management team in a constructive, private manner since 2017.
SCT includes treasury share cancellation as part of its Shareholder Return Policy, but we would not characterise this as a shareholder return.
The Company has destroyed shareholder value, with a track record of decision making that appears to ignore the interests of its minority shareholders.
If the Board does not meaningfully engage with us on our recommendations to enhance shareholder value at SCT, we intend to share our views with our fellow shareholders in due course.

Multiple Myeloma Epidemiology Analysis and Forecast to 2032: Focus on 8MM - US, France, Germany, Italy, Spain, UK, Japan, and Urban China - ResearchAndMarkets.com

Retrieved on:

Monday, December 11, 2023

Health, Oncology, Epidemiology, Incidence, Multiple myeloma, AGR, SCT, Therapy, Diagnosis, Risk, Mobile phone, Dietary supplement, Vaccine, Pharmaceutical industry

The "Multiple Myeloma Epidemiology Analysis and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Multiple Myeloma Epidemiology Analysis and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
In 2032, the US will have the highest number of diagnosed incident cases of MM in the 8MM, with 35,307 diagnosed incident cases, whereas Spain will have the fewest diagnosed incident cases with 3,517 cases.
The report includes a 10-year epidemiology forecast for the diagnosed incident and diagnosed prevalent cases of MM.
The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of MM across these markets.

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

Retrieved on:

Tuesday, December 12, 2023

“The clinical results and real-world evidence presented at ASH clearly support the potential for long-term response and safety of Tecartus in aggressive blood cancers for which patients have limited treatment options,” said Frank Neumann, MD, PhD, Senior Vice President, Global Head of Clinical Development, Kite.

Key Points:

“The clinical results and real-world evidence presented at ASH clearly support the potential for long-term response and safety of Tecartus in aggressive blood cancers for which patients have limited treatment options,” said Frank Neumann, MD, PhD, Senior Vice President, Global Head of Clinical Development, Kite.
The median OS for patients with complete response (CR) (n=46) was 58.7 months.
Efficacy and safety outcomes for 23 patients with R/R MCL enrolled in ZUMA-18, a multicenter, open-label, expanded-access study of Tecartus, were also presented.
An analysis of a CIBMTR observational database of R/R MCL patients receiving Tecartus from 84 U.S. centers was presented.

Palliser Capital Presents Recommendations to Unlock Value and Catalyze Growth at Samsung C&T

Retrieved on:

Wednesday, December 6, 2023

Finance, Public Relations, Investor Relations, Communications, Professional Services, Asset Management, CIO, SCT, Growth, Capital, Multimedia, Conference, Palliser, Samsung

Palliser Capital (“Palliser”), a long-standing investor in Samsung C&T Corp. (“SCT” or “the Company”), with a 0.62%1 shareholding, today published a comprehensive presentation detailing opportunities to unlock significant long-term value at SCT following Palliser’s participation at the 10th Annual Sohn London Investment Conference.

Key Points:

Palliser Capital (“Palliser”), a long-standing investor in Samsung C&T Corp. (“SCT” or “the Company”), with a 0.62%1 shareholding, today published a comprehensive presentation detailing opportunities to unlock significant long-term value at SCT following Palliser’s participation at the 10th Annual Sohn London Investment Conference.
Palliser's presentation highlights the US$25BN disparity between SCT’s share price and its intrinsic market value, equivalent to a 63% discount (the “SCT Value Gap”), and the clear and actionable measures SCT can take to eradicate that discount while catalyzing the next phase of growth for the Company.
Unfortunately, SCT is trading at a deep discount, signaling investor concerns over capital investment and value creation, despite good underlying fundamentals.
We believe our comprehensive yet practical value enhancement recommendations, if implemented, will enable the Company to significantly narrow, if not remove, this discount and realize its intrinsic value while simultaneously driving long-term growth.